Peri-procedural myocardial injury: 2005 update.

During the past three decades, percutaneous coronary intervention has become one of the cardinal treatment strategies for stenotic coronary artery disease. Technical advances, including the introduction of new devices such as stents, have expanded the interventional capabilities of balloon angioplasty. At the same time, there has been a decline in the rate of major adverse cardiac events, including Q-wave acute myocardial infarction, emergency coronary artery bypass grafting, and cardiac death. Despite these advances, the incidence of post-procedural cardiac marker elevation has not substantially decreased since the first serial assessment 20 years ago. As of now, these post-procedural cardiac marker elevations are considered to represent peri-procedural myocardial injury (PMI) with worse long-term outcome potential. Recent progress has been made for the identification of two main PMI patterns, one near the intervention site (proximal type, PMI type I) and one in the distal perfusion territory of the treated coronary artery (distal type, PMI type II) as well as for preventive strategies. Integrating these new developments into the wealth of clinical information on this topic, this review aims at giving a current perspective on the entity of PMI.

[1]  M. Togni,et al.  Percutaneous coronary interventions in Europe 1992-2003. , 2004, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.

[2]  P. D. de Feyter,et al.  Angiographic, intravascular ultrasound, and fractional flow reserve evaluation of direct stenting vs. conventional stenting using BeStent2 in a multicentre randomized trial. , 2005, European heart journal.

[3]  M. Ray,et al.  Platelet-monocyte aggregates predict troponin rise after percutaneous coronary intervention and are inhibited by Abciximab. , 2005, International journal of cardiology.

[4]  W. Herzog,et al.  The relation of dosing to clopidogrel responsiveness and the incidence of high post-treatment platelet aggregation in patients undergoing coronary stenting. , 2005, Journal of the American College of Cardiology.

[5]  W. Chilian,et al.  Cardiac myocytes control release of endothelin-1 in coronary vasculature. , 2005, American journal of physiology. Heart and circulatory physiology.

[6]  V. Pasceri,et al.  Randomized Trial of High Loading Dose of Clopidogrel for Reduction of Periprocedural Myocardial Infarction in Patients Undergoing Coronary Intervention: Results From the ARMYDA-2 (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty) Study* , 2005, Circulation.

[7]  K. Mensah,et al.  Failure to protect the myocardium against ischemia/reperfusion injury after chronic atorvastatin treatment is recaptured by acute atorvastatin treatment: a potential role for phosphatase and tensin homolog deleted on chromosome ten? , 2005, Journal of the American College of Cardiology.

[8]  Masato Nakamura,et al.  Fate of unprotected side branches as related to embolic complications during stent implantation for acute coronary syndromes using a distal protection procedure. , 2005, The American journal of cardiology.

[9]  S. Petersen,et al.  Troponin Elevation After Percutaneous Coronary Intervention Directly Represents the Extent of Irreversible Myocardial Injury: Insights From Cardiovascular Magnetic Resonance Imaging , 2005, Circulation.

[10]  F. Wuyts,et al.  Does pre-treatment with aspirin and loading dose clopidogrel obviate the need for glycoprotein IIb/IIIa antagonists during elective coronary stenting? A focus on peri-procedural myonecrosis. , 2005, European heart journal.

[11]  E. Ohman,et al.  Antithrombotic therapy during percutaneous coronary intervention: The seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy , 2005 .

[12]  J. Ambrose,et al.  Preprocedural plasma C-reactive protein levels, postprocedural creatine kinase-MB release, and long-term prognosis after successful coronary stenting (four-year results from the GENERATION study). , 2005, The American journal of cardiology.

[13]  G. Stone,et al.  Creatine kinase-MB enzyme elevation and long-term clinical events after successful coronary stenting in lesions with ruptured plaque. , 2005, The American journal of cardiology.

[14]  R. Harrington “Randomized Trial of High Loading Dose of Clopidogrel for Reduction of Periprocedural Myocardial Infarction in Patients Undergoing Coronary Intervention: Results From the ARMYDA-2 (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty) Study” , 2005 .

[15]  R. Harrington Antithrombotic therapy during percutaneous coronary intervention , 2005, Journal of Thrombosis and Thrombolysis.

[16]  D. Ardissino,et al.  Impact of the elevation of biochemical markers of myocardial damage on long-term mortality after percutaneous coronary intervention: results of the CK-MB and PCI study. , 2005, European heart journal.

[17]  J. Solís,et al.  Predictors and prognostic value of myocardial injury following stent implantation. , 2004, International journal of cardiology.

[18]  M. Togni,et al.  Percutaneous coronary interventions in Europe 1992-2001. , 2004, European heart journal.

[19]  MasatsuguHori,et al.  Optimal Windows of Statin Use for Immediate Infarct Limitation , 2004 .

[20]  M. Hori,et al.  Optimal Windows of Statin Use for Immediate Infarct Limitation: 5′-Nucleotidase as Another Downstream Molecule of Phosphatidylinositol 3-Kinase , 2004, Circulation.

[21]  A. Colombo,et al.  Statin administration before percutaneous coronary intervention: impact on periprocedural myocardial infarction. , 2004, European heart journal.

[22]  S. Baldassarre,et al.  Elevations in Troponin I After Percutaneous Coronary Interventions Are Associated With Abnormal Tissue-Level Perfusion in High-Risk Patients With Non–ST-Segment–Elevation Acute Coronary Syndromes , 2004, Circulation.

[23]  E. Topol,et al.  Lack of clopidogrel pretreatment effect on the relative efficacy of bivalirudin with provisional glycoprotein IIb/IIIa blockade compared to heparin with routine glycoprotein IIb/IIIa blockade: a REPLACE-2 substudy. , 2004, Journal of the American College of Cardiology.

[24]  S. Steinhubl,et al.  Comparison of long-term usefulness of clopidogrel therapy after the first percutaneous coronary intervention or coronary artery bypass grafting versus that after the second or repeat intervention. , 2004, The American journal of cardiology.

[25]  E. Ohman,et al.  Antithrombotic therapy during percutaneous coronary intervention: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. , 2004, Chest.

[26]  K. Shimada,et al.  Early Statin Treatment in Patients With Acute Coronary Syndrome: Demonstration of the Beneficial Effect on Atherosclerotic Lesions by Serial Volumetric Intravascular Ultrasound Analysis During Half a Year After Coronary Event: The ESTABLISH Study , 2004, Circulation.

[27]  E. Braunwald,et al.  Association between duration of tirofiban therapy before percutaneous intervention and tissue level perfusion (a TACTICS-TIMI 18 substudy). , 2004, The American journal of cardiology.

[28]  E. Topol,et al.  Long-term efficacy of bivalirudin and provisional glycoprotein IIb/IIIa blockade vs heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary revascularization: REPLACE-2 randomized trial. , 2004, JAMA.

[29]  V. Pasceri,et al.  Randomized Trial of Atorvastatin for Reduction of Myocardial Damage During Coronary Intervention: Results From the ARMYDA (Atorvastatin for Reduction of MYocardial Damage during Angioplasty) Study , 2004, Circulation.

[30]  A. Angelini,et al.  Distal Protection With a Filter Device During Coronary Stenting in Patients With Stable and Unstable Angina , 2004, Circulation.

[31]  R. Schiele,et al.  Too little aspirin for secondary prevention after acute myocardial infarction in patients at high risk for cardiovascular events: Results from the MITRA study. , 2004, American heart journal.

[32]  A. Defranco,et al.  Prognostic Implication of Anemia on In-Hospital Outcomes After Percutaneous Coronary Intervention , 2004, Circulation.

[33]  G. Laarman,et al.  Lack of efficacy of clopidogrel pre-treatment in the prevention of myocardial damage after elective stent implantation. , 2004, Journal of the American College of Cardiology.

[34]  R. Ferrari,et al.  The additive value of tirofiban administered with the high-dose bolus in the prevention of ischemic complications during high-risk coronary angioplasty: the ADVANCE Trial. , 2004, Journal of the American College of Cardiology.

[35]  G. Heusch Coronary microembolization*1 , 2004 .

[36]  P. Théroux,et al.  Clopidogrel inhibits platelet-leukocyte interactions and thrombin receptor agonist peptide-induced platelet activation in patients with an acute coronary syndrome. , 2004, Journal of the American College of Cardiology.

[37]  I. Iakovou,et al.  Creatine kinase-myocardial band isoenzyme elevation after percutaneous coronary interventions using sirolimus-eluting stents. , 2004, The American journal of cardiology.

[38]  N. Lakkis,et al.  Use of statins prior to percutaneous coronary intervention reduces myonecrosis and improves clinical outcome , 2004, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.

[39]  K. Kent,et al.  Impact of major side branch on periprocedural enzyme elevation and long-term outcome in patients undergoing percutaneous coronary intervention and brachytherapy for in-stent restenosis. , 2004, American Journal of Cardiology.

[40]  R. Erbel,et al.  Glucocorticoid Treatment Prevents Progressive Myocardial Dysfunction Resulting From Experimental Coronary Microembolization , 2004, Circulation.

[41]  E. Topol,et al.  Comparison of bivalirudin versus heparin during percutaneous coronary intervention (the Randomized Evaluation of PCI Linking Angiomax to Reduced Clinical Events [REPLACE]-1 trial). , 2004, The American journal of cardiology.

[42]  E. Edelman,et al.  Embolic Protection With Filtering or Occlusion Balloons During Saphenous Vein Graft Stenting Retrieves Identical Volumes and Sizes of Particulate Debris , 2004, Circulation.

[43]  C. Knackstedt,et al.  Randomized comparison of direct stenting with predilatation followed by stenting on vessel trauma and restenosis. , 2004, American heart journal.

[44]  Shinji Mito,et al.  Long-term effects of quinapril with high affinity for tissue angiotensin-converting enzyme after coronary intervention in Japanese. , 2004, American heart journal.

[45]  C. Lau,et al.  Aspirin resistance is associated with a high incidence of myonecrosis after non-urgent percutaneous coronary intervention despite clopidogrel pretreatment. , 2004, Journal of the American College of Cardiology.

[46]  S. Mehta,et al.  Incidence, predictors, and clinical significance of troponin-I elevation without creatine kinase elevation following percutaneous coronary interventions. , 2004, The American journal of cardiology.

[47]  A. Prakash,et al.  Predictors of troponin elevation after percutaneous coronary intervention. , 2004, The American journal of cardiology.

[48]  A. Kastrati,et al.  A clinical trial of abciximab in elective percutaneous coronary intervention after pretreatment with clopidogrel , 2004 .

[49]  P. Doevendans,et al.  Role of apoptosis in reperfusion injury. , 2004, Cardiovascular research.

[50]  G. Jennings,et al.  Serotonin blockade protects against early microvascular constriction following atherosclerotic plaque rupture. , 2004, European journal of pharmacology.

[51]  K. Kent,et al.  Usefulness of periprocedural creatinine phosphokinase-MB release to predict adverse outcomes after intracoronary radiation therapy for in-stent restenosis. , 2004, The American journal of cardiology.

[52]  A. Kastrati,et al.  Intracoronary stenting and angiographic results: Restenosis after direct stenting versus stenting with predilation in patients with symptomatic coronary artery disease (ISAR‐DIRECT trial) , 2004, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.

[53]  Ori Ben-Yehuda,et al.  Effects of glycoprotein IIb/IIIa inhibition on microvascular flow after coronary reperfusion. A quantitative myocardial contrast echocardiography study. , 2004, Journal of the American College of Cardiology.

[54]  A. Kastrati,et al.  A clinical trial of abciximab in elective percutaneous coronary intervention after pretreatment with clopidogrel. , 2004, The New England journal of medicine.

[55]  R. Kim,et al.  Myonecrosis following stent placement: association between impaired TIMI myocardial perfusion grade and MRI visualization of microinfarction. , 2002, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.

[56]  M. Roea,et al.  Creatine kinase-MB elevation after percutaneous coronary intervention predicts adverse outcomes in patients with acute coronary syndromes , 2004 .

[57]  T. Nageh,et al.  Cardiac troponin T and I and creatine kinase-MB as markers of myocardial injury and predictors of outcome following percutaneous coronary intervention. , 2003, International journal of cardiology.

[58]  R. Schiele,et al.  Comparison of different cardiac markers in monitoring percutaneous coronary interventions with frequent use of stents and gpIIbIIIa-antagonists , 2003, Zeitschrift für Kardiologie.

[59]  K. Kent,et al.  Comparison of creatine kinase elevation and outcome of comparison of percutaneous coronary intervention for saphenous vein graft in-stent restenosis versus de novo stenosis. , 2003, The American journal of cardiology.

[60]  J. Ioannidis,et al.  Mortality risk conferred by small elevations of creatine kinase-MB isoenzyme after percutaneous coronary intervention. , 2003, Journal of the American College of Cardiology.

[61]  Deepak L. Bhatt,et al.  Triple antiplatelet therapy during percutaneous coronary intervention is associated withimproved outcomes including one-year survival , 2003 .

[62]  Deepak L. Bhatt,et al.  Preprocedural white blood cell count and death after percutaneous coronary intervention. , 2003, American heart journal.

[63]  L. Klein,et al.  Society of cardiac angiography and interventions: Suggested management of the no‐reflow phenomenon in the cardiac catheterization laboratory , 2003, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.

[64]  V. Hasselblad,et al.  Reduction of myocardial ischemic injury following coronary intervention (the MC-1 to Eliminate Necrosis and Damage trial). , 2003, The American journal of cardiology.

[65]  K. Kent,et al.  Effect of direct stenting on clinical outcome in patients treated with percutaneous coronary intervention on saphenous vein graft. , 2003, American heart journal.

[66]  T. Meinertz,et al.  Platelet Glycoprotein IIb/IIIa Receptor Blockade Improves Vascular Nitric Oxide Bioavailability in Patients With Coronary Artery Disease , 2003, Circulation.

[67]  G. Stone,et al.  Randomized Comparison of Distal Protection With a Filter-Based Catheter and a Balloon Occlusion and Aspiration System During Percutaneous Intervention of Diseased Saphenous Vein Aorto-Coronary Bypass Grafts , 2003, Circulation.

[68]  R. Nieuwland,et al.  Microparticles in cardiovascular diseases. , 2003, Cardiovascular research.

[69]  A. Jacobs,et al.  Management of Patients Undergoing Percutaneous Coronary Revascularization , 2003, Annals of Internal Medicine.

[70]  M. Keane,et al.  Role of cardiac troponin T in the long-term risk stratification of patients undergoing percutaneous coronary intervention. , 2003, European heart journal.

[71]  P. Modesti,et al.  Immunomediated and Ischemia-Independent Inflammation of Coronary Microvessels in Unstable Angina , 2003, Circulation research.

[72]  B. Uretsky,et al.  Distal Myocardial Protection During Percutaneous Coronary Intervention With an Intracoronary &bgr;‐Blocker , 2003, Circulation.

[73]  W. Weintraub,et al.  Prognostic implication of creatine kinase release after elective percutaneous coronary intervention in the pre-IIb/IIIa antagonist era. , 2003, American heart journal.

[74]  E. Mahmud,et al.  Patients at low risk for periprocedural myocardial infarction can be identified by assessment immediately following percutaneous coronary intervention. , 2003, The Journal of invasive cardiology.

[75]  P. Collinson,et al.  Ischemia Modified Albumin Is a Sensitive Marker of Myocardial Ischemia After Percutaneous Coronary Intervention , 2003, Circulation.

[76]  B. Nallamothu,et al.  Prognostic implication of troponin I elevation after percutaneous coronary intervention. , 2003, The American journal of cardiology.

[77]  F. Burzotta,et al.  Stenting of Culprit Lesions in Unstable Angina Leads to a Marked Reduction in Plaque Burden: A Major Role of Plaque Embolization?: A Serial Intravascular Ultrasound Study , 2003, Circulation.

[78]  M. Gawaz,et al.  Prevalence of clopidogrel non-responders among patients with stable angina pectoris scheduled for elective coronary stent placement , 2003, Thrombosis and Haemostasis.

[79]  Deepak L. Bhatt,et al.  Relation of Inflammation and Benefit of Statins After Percutaneous Coronary Interventions , 2003, Circulation.

[80]  A. Damonte,et al.  Multicenter randomized comparison of direct vs. conventional stenting: The DIRECTO trial , 2003, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.

[81]  W. Voelker,et al.  Cytokine response after percutaneous coronary intervention in stable angina: effect of selective glycoprotein IIb/IIIa receptor antagonism. , 2003, American heart journal.

[82]  G. Stone,et al.  Effect of percutaneous coronary interventions for in-stent restenosis in degenerated saphenous vein grafts without distal embolic protection. , 2003, Journal of the American College of Cardiology.

[83]  T. Nageh,et al.  Direct stenting may limit myocardial injury during percutaneous coronary intervention. , 2003, The Journal of invasive cardiology.

[84]  N. Weissman,et al.  Impact of renal function on morbidity and mortality after percutaneous aortocoronary saphenous vein graft intervention. , 2003, American heart journal.

[85]  R. Bonow,et al.  Troponin I elevation and cardiac events after percutaneous coronary intervention. , 2003, American heart journal.

[86]  E. Topol,et al.  Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trial. , 2003, JAMA.

[87]  D. Yellon,et al.  Atorvastatin, administered at the onset of reperfusion, and independent of lipid lowering, protects the myocardium by up-regulating a pro-survival pathway. , 2003, Journal of the American College of Cardiology.

[88]  Y. Atmaca,et al.  The prevention of minor myocardial injury with ticlopidine pretreatment in patients undergoing elective coronary stenting. , 2003, International journal of cardiology.

[89]  Y. Atmaca,et al.  Comparison of clopidogrel versus ticlopidine for prevention of minor myocardial injury after elective coronary stenting. , 2003, International journal of cardiology.

[90]  George Dangas,et al.  Increased CK-MB release is a "trade-off" for optimal stent implantation: an intravascular ultrasound study. , 2002, Journal of the American College of Cardiology.

[91]  Samin K. Sharma,et al.  Postprocedure chest pain after coronary stenting: implications on clinical restenosis. , 2003, Journal of the American College of Cardiology.

[92]  Deepak L. Bhatt,et al.  Safety of concomitant therapy with eptifibatide and enoxaparin in patients undergoing percutaneous coronary intervention: results of the Coronary Revascularization Using Integrilin and Single bolus Enoxaparin Study. , 2003, Journal of the American College of Cardiology.

[93]  N. Yoshimoto,et al.  Ischaemic preconditioning and outcomes after angioplasty: effects of drug therapy. , 2003, Drugs.

[94]  A. J. J. IJsselmuidena,et al.  Direct coronary stent implantation does not reduce the incidence of in-stent restenosis or major adverse cardiac events Six month results of a randomized trial , 2003 .

[95]  Deepak L. Bhatt,et al.  Triple antiplatelet therapy during percutaneous coronary intervention is associated with improved outcomes including one-year survival: results from the Do Tirofiban and ReoProGive Similar Efficacy Outcome Trial (TARGET). , 2003, Journal of the American College of Cardiology.

[96]  H. Gold,et al.  Enhanced extracellular matrix accumulation in restenosis of coronary arteries after stent deployment. , 2002, Journal of the American College of Cardiology.

[97]  E. Topol,et al.  Association between CK-MB elevation after percutaneous or surgical revascularization and three-year mortality. , 2002, Journal of the American College of Cardiology.

[98]  C. Di Mario,et al.  Effects of selective alpha1- and alpha2-adrenergic blockade on coronary flow reserve after coronary stenting. , 2002, Circulation.

[99]  W. Daniel,et al.  Direct coronary stenting versus predilatation followed by stent placement. , 2002, The American journal of cardiology.

[100]  Eric J Topol,et al.  Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. , 2002, JAMA.

[101]  A. Jacobs,et al.  Comparison of in-hospital and one-year outcomes in patients with and without diabetes mellitus undergoing percutaneous catheter intervention (from the National Heart, Lung, and Blood Institute Dynamic Registry). , 2002, The American journal of cardiology.

[102]  P. Serruys,et al.  Fluvastatin for Prevention of Cardiac Events Following Successful First Percutaneous Coronary Intervention , 2002 .

[103]  R. Califf,et al.  Effect of abciximab on angiographic complications during percutaneous coronary stenting in the Evaluation of Platelet IIb/IIIa Inhibition in Stenting Trial (EPISTENT). , 2002, The American journal of cardiology.

[104]  G. Stone,et al.  Distal filter protection during saphenous vein graft stenting: technical and clinical correlates of efficacy. , 2002, Journal of the American College of Cardiology.

[105]  R. Erbel,et al.  Preprocedural Statin Medication Reduces the Extent of Periprocedural Non–Q-Wave Myocardial Infarction , 2002, Circulation.

[106]  M. Kern,et al.  Early changes in coronary flow physiology after balloon angioplasty or stenting: A 24‐hour Doppler flow velocity study , 2002, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.

[107]  E. Topol,et al.  Death Following Creatine Kinase-MB Elevation After Coronary Intervention: Identification of an Early Risk Period: Importance of Creatine Kinase-MB Level, Completeness of Revascularization, Ventricular Function, and Probable Benefit of Statin Therapy , 2002, Circulation.

[108]  Samin K. Sharma,et al.  Effectiveness of tirofiban, eptifibatide, and abciximab in minimizing myocardial necrosis during percutaneous coronary intervention (TEAM pilot study). , 2002, The American journal of cardiology.

[109]  V. Sánchez-Margalet,et al.  Inflammatory Response to Coronary Stent Implantation in Patients with Unstable Angina , 2002, Clinical chemistry and laboratory medicine.

[110]  Deepak L. Bhatt,et al.  Mortality benefit of beta-blockade after successful elective percutaneous coronary intervention. , 2002, Journal of the American College of Cardiology.

[111]  K. Harre,et al.  Effect of additional temporary glycoprotein IIb/IIIa receptor inhibition on troponin release in elective percutaneous coronary interventions after pretreatment with aspirin and clopidogrel (TOPSTAR trial). , 2002, Journal of the American College of Cardiology.

[112]  A. Çengel,et al.  Frequency of cardiac troponin-T elevation after successful direct stenting , 2002, Acta cardiologica.

[113]  G. Ferns,et al.  Biochemical detection of minor myocardial injury after elective, uncomplicated, successful percutaneous coronary intervention in patients with stable angina: clinical outcome , 2002, Annals of Clinical Biochemistry.

[114]  P. Serruys,et al.  Fluvastatin for prevention of cardiac events following successful first percutaneous coronary intervention: a randomized controlled trial. , 2002, JAMA.

[115]  M. Graham,et al.  Abciximab Attenuates Coronary Microvascular Endothelial Dysfunction After Coronary Stenting , 2002, Circulation.

[116]  V. Hasselblad,et al.  Prognostic significance of elevated troponin I after percutaneous coronary intervention. , 2002, Journal of the American College of Cardiology.

[117]  A. Hingorani,et al.  Prevention of Inflammation-Induced Endothelial Dysfunction: A Novel Vasculo-Protective Action of Aspirin , 2002, Circulation.

[118]  E. Topol,et al.  Frequency and long-term impact of myonecrosis after coronary stenting. , 2002, European heart journal.

[119]  Eric J Topol,et al.  Prognostic significance of creatine kinase-MB elevation after percutaneous coronary intervention in patients with chronic renal dysfunction. , 2002, American heart journal.

[120]  W. Boden,et al.  Long-term follow-up of patients with increased cardiac troponin concentrations following percutaneous coronary intervention. , 2002, The American journal of cardiology.

[121]  R. Erbel,et al.  Prognostic implication of cardiac troponin T increase following stent implantation , 2002, Heart.

[122]  E. Topol,et al.  Impact of Clinical Syndrome Acuity on the Differential Response to 2 Glycoprotein IIb/IIIa Inhibitors in Patients Undergoing Coronary Stenting: The TARGET Trial* , 2002, Circulation.

[123]  U. Berglund,et al.  Clopidogrel treatment before percutaneous coronary intervention reduces adverse cardiac events. , 2002, The Journal of invasive cardiology.

[124]  G. Ferns,et al.  Association of systemic inflammatory state with troponin I elevation after elective uncomplicated percutaneous coronary intervention. , 2002, The American journal of cardiology.

[125]  G. Maurer,et al.  Coronary no-reflow is caused by shedding of active tissue factor from dissected atherosclerotic plaque. , 2002, Blood.

[126]  P. Serruys,et al.  Coronary Flow Velocity Reserve After Percutaneous Interventions Is Predictive of Periprocedural Outcome , 2002, Circulation.

[127]  A. Çengel,et al.  Myocardial injury after apparently successful coronary stenting with or without balloon dilation: direct versus conventional stenting. , 2002, The Journal of invasive cardiology.

[128]  J. Ruiz-Nodar,et al.  Direct coronary stenting versus stenting with balloon pre-dilation: immediate and follow-up results of a multicentre, prospective, randomized study. The DISCO trial. DIrect Stenting of COronary Arteries. , 2002, European heart journal.

[129]  K. Ray Abciximab suppresses the rise in levels of circulating inflammatory markers after percutaneous coronary revascularization. , 2002, Circulation.

[130]  M. Leon,et al.  Randomized Trial of a Distal Embolic Protection Device During Percutaneous Intervention of Saphenous Vein Aorto-Coronary Bypass Grafts , 2002, Circulation.

[131]  E. Topol,et al.  Comparison of long-term survival following non-Q-wave creatine kinase elevation after percutaneous coronary intervention in patients discharged on a beta blocker versus those not so treated. , 2002, The American journal of cardiology.

[132]  Chest pain after coronary artery stent implantation. , 2002, The American journal of cardiology.

[133]  G. Stone,et al.  Postprocedure creatine kinase-MB elevation and baseline left ventricular dysfunction predict one-year mortality after percutaneous coronary intervention. , 2002, The American journal of cardiology.

[134]  S. Harder,et al.  Clopidogrel, but not abciximab, reduces platelet leukocyte conjugates and P‐selectin expression in a human ex vivo in vitro model , 2002, Clinical pharmacology and therapeutics.

[135]  Deepak L. Bhatt,et al.  Early and Sustained Survival Benefit Associated With Statin Therapy at the Time of Percutaneous Coronary Intervention , 2002, Circulation.

[136]  R. Califf,et al.  Long-term efficacy of platelet glycoprotein IIb/IIIa integrin blockade with eptifibatide in coronary stent intervention. , 2002, JAMA.

[137]  M. Simoons,et al.  Minor Myocardial Damage and Prognosis: Are Spontaneous and Percutaneous Coronary Intervention–Related Events Different? , 2002, Circulation.

[138]  K. Kent,et al.  Prognostic value of cardiac troponin I elevation after percutaneous coronary intervention in patients with chronic renal insufficiency: A 12‐month outcome analysis , 2002, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.

[139]  R. Erbel,et al.  Reduced coronary and inotropic reserves with coronary microembolization. , 2002, American journal of physiology. Heart and circulatory physiology.

[140]  E. Ribeiro,et al.  Comparison of direct stenting versus stenting with predilation for the treatment of selected coronary narrowings. , 2002, The American journal of cardiology.

[141]  G. Stone,et al.  Clinical outcome following percutaneous coronary interventions in patients with chronic renal failure , 2002, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.

[142]  T. Nageh,et al.  Cardiac troponin I for risk stratification following percutaneous coronary artery intervention in acute coronary syndromes , 2002, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.

[143]  Andrew J Taylor,et al.  Experimental Rupture of Atherosclerotic Lesions Increases Distal Vascular Resistance: A Limiting Factor to the Success of Infarct Angioplasty , 2002, Arteriosclerosis, thrombosis, and vascular biology.

[144]  S. Murphy,et al.  Relationship of creatine kinase-myocardial band release to Thrombolysis in Myocardial Infarction perfusion grade after intracoronary stent placement: an ESPRIT substudy. , 2002, American heart journal.

[145]  P. Fitzgerald,et al.  Comparison of PRE-dilatation vs direct stenting in coronary treatment using the Medtronic AVE S670 Coronary Stent System (the PREDICT trial). , 2001, The American journal of cardiology.

[146]  E. Topol,et al.  Bivalirudin versus heparin during coronary angioplasty for unstable or postinfarction angina: Final report reanalysis of the Bivalirudin Angioplasty Study. , 2001, American heart journal.

[147]  Samin K. Sharma,et al.  Reduction in periprocedural enzyme elevation by abciximab after rotational atherectomy of type B2 lesions: Results of the Rota ReoPro randomized trial. , 2001, American heart journal.

[148]  E. Topol,et al.  &bgr;-Blockers Before Percutaneous Coronary Intervention Do Not Attenuate Postprocedural Creatine Kinase Isoenzyme Rise , 2001, Circulation.

[149]  A. Yeung,et al.  Prevention of Distal Embolization During Coronary Angioplasty in Saphenous Vein Grafts and Native Vessels Using Porous Filter Protection , 2001, Circulation.

[150]  K. Ravi,et al.  A randomized trial of stenting with or without balloon predilation for the treatment of coronary artery disease. , 2001, American heart journal.

[151]  S. Sdringola,et al.  Effects of clopidogrel pretreatment before percutaneous coronary intervention in patients treated with glycoprotein IIb/IIIa inhibitors (abciximab or tirofiban). , 2001, The American journal of cardiology.

[152]  D. Lefer,et al.  Cardioprotective actions of acute HMG-CoA reductase inhibition in the setting of myocardial infarction. , 2001, Acta physiologica Scandinavica.

[153]  C. Leclercq,et al.  Randomised comparison of coronary stenting with and without balloon predilatation in selected patients , 2001, Heart.

[154]  Deepak L. Bhatt,et al.  Incremental Prognostic Value of Elevated Baseline C-Reactive Protein Among Established Markers of Risk in Percutaneous Coronary Intervention , 2001, Circulation.

[155]  Salim Yusuf,et al.  Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study , 2001, The Lancet.

[156]  G. Stone,et al.  Differential Impact on Survival of Electrocardiographic Q-Wave Versus Enzymatic Myocardial Infarction After Percutaneous Intervention , 2001 .

[157]  G. Stone,et al.  Differential Impact on Survival of Electrocardiographic Q-Wave Versus Enzymatic Myocardial Infarction After Percutaneous Intervention: A Device-Specific Analysis of 7147 Patients , 2001, Circulation.

[158]  K. Kent,et al.  Prognostic value of cardiac troponin I re-elevation following percutaneous coronary intervention in high-risk patients with acute coronary syndromes. , 2001, The American journal of cardiology.

[159]  E. Topol,et al.  Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization. , 2001, The New England journal of medicine.

[160]  David O. Williams,et al.  ACC/AHA Guidelines for Percutaneous Coronary Intervention (Revision of the 1993 PTCA Guidelines)—Executive Summary , 2001 .

[161]  K A Eagle,et al.  ACC/AHA guidelines of percutaneous coronary interventions (revision of the 1993 PTCA guidelines)--executive summary. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (committee to revise the 1993 guidelines for percutaneous transluminal coro , 2001, Journal of the American College of Cardiology.

[162]  R. Kim,et al.  Visualization of Discrete Microinfarction After Percutaneous Coronary Intervention Associated With Mild Creatine Kinase-MB Elevation , 2001, Circulation.

[163]  G. Ferns,et al.  Minor myocardial injury after elective uncomplicated successful PTCA with or without stenting: Detection by cardiac troponins , 2001, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.

[164]  A. Schmermund,et al.  Abnormal Coronary Flow Velocity Reserve After Coronary Intervention Is Associated With Cardiac Marker Elevation , 2001, Circulation.

[165]  D. Carrié,et al.  Comparison of direct coronary stenting with and without balloon predilatation in patients with stable angina pectoris. BET (Benefit Evaluation of Direct Coronary Stenting) Study Group. , 2001, The American journal of cardiology.

[166]  K. Thygesen,et al.  Erratum: Myocardial infarction redefined - A consensus document of the Joint European Society of Cardiology/American College of Cardiology Committee for the Redefinition of Myocardial Infarction (Journal of the American College of Cardiology (2000) 36 (959-969)) , 2001 .

[167]  M. Pfisterer,et al.  Chest pain early after percutaneous coronary intervention: incidence and relation to ECG changes, cardiac enzymes and follow-up events. , 2001, The Journal of invasive cardiology.

[168]  R. Erbel,et al.  Coronary microembolization. , 2001, Progress in cardiovascular diseases.

[169]  G. FitzGerald,et al.  Angioplasty increases coronary sinus F2-isoprostane formation: evidence for in vivo oxidative stress during PTCA. , 2001, Journal of the American College of Cardiology.

[170]  H. White,et al.  Inhibition of the Sodium-Hydrogen Exchanger With Cariporide to Prevent Myocardial Infarction in High-Risk Ischemic Situations: Main Results of the GUARDIAN Trial , 2000, Circulation.

[171]  I. Palacios,et al.  Are Patients With Renal Failure Good Candidates for Percutaneous Coronary Revascularization in the New Device Era? , 2000, Circulation.

[172]  T. Henry,et al.  Monitoring plasma cardiac troponin I for the detection of myocardial injury after percutaneous transluminal coronary angioplasty. , 2000, Clinica chimica acta; international journal of clinical chemistry.

[173]  R. Erbel,et al.  Perfusion-contraction mismatch with coronary microvascular obstruction: role of inflammation. , 2000, American journal of physiology. Heart and circulatory physiology.

[174]  T. Miyazaki,et al.  Comparison of activation process of platelets and neutrophils after coronary stent implantation versus balloon angioplasty for stable angina pectoris. , 2000, The American journal of cardiology.

[175]  T. Nageh,et al.  Comparison of cardiac troponin T and I and CK-MB for the detection of minor myocardial damage during interventional cardiac procedures , 2000, Annals of clinical biochemistry.

[176]  B. Strauss,et al.  Evaluation of the role of abciximab (Reopro) as a rescue agent during percutaneous coronary interventions: In‐hospital and six‐month outcomes , 2000, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.

[177]  G. Stone,et al.  Clinical outcomes following "rescue" administration of abciximab in patients undergoing percutaneous coronary angioplasty. , 2000, The Journal of invasive cardiology.

[178]  G. Stone,et al.  Prognostic value of recurrent episodes of creatine kinase‐MB elevation following repeated catheter‐based coronary interventions , 2000, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.

[179]  P. Boekstegers,et al.  c7E3Fab Reduces Postischemic Leukocyte-Thrombocyte Interaction Mediated by Fibrinogen: Implications for Myocardial Reperfusion Injury , 2000, Arteriosclerosis, thrombosis, and vascular biology.

[180]  D. Brown,et al.  Relation between coronary atherosclerotic plaque burden and cardiac enzyme elevation following percutaneous coronary intervention. , 2000, The American journal of cardiology.

[181]  Hugo A. Katus,et al.  Myocardial infarction redefined--a consensus document of The Joint European Society of Cardiology/American College of Cardiology Committee for the redefinition of myocardial infarction. , 2000, European heart journal.

[182]  R. Blumenthal,et al.  Medical therapy versus coronary angioplasty in stable coronary artery disease: a critical review of the literature. , 2000, Journal of the American College of Cardiology.

[183]  A. Remppis,et al.  Cardiac Troponin T Levels at 96 Hours Reflect Myocardial Infarct Size: A Pathoanatomical Study , 2000, Cardiology.

[184]  M. Bertrand,et al.  Double-blind study of the safety of clopidogrel with and without a loading dose in combination with aspirin compared with ticlopidine in combination with aspirin after coronary stenting : the clopidogrel aspirin stent international cooperative study (CLASSICS). , 2000, Circulation.

[185]  I. Meredith,et al.  A randomized study of direct coronary stent delivery compared with stenting after predilatation: The NIR future trial , 2000, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.

[186]  F. Verheugt,et al.  Effect of coumarins started before coronary angioplasty on acute complications and long-term follow-up: a randomized trial. , 2000, Circulation.

[187]  A. Kini,et al.  Cardioprotective effect of prior beta-blocker therapy in reducing creatine kinase-MB elevation after coronary intervention: benefit is extended to improvement in intermediate-term survival. , 2000, Circulation.

[188]  A. Lansky,et al.  Mechanism of lumen enlargement during intracoronary stent implantation: an intravascular ultrasound study. , 2000, Circulation.

[189]  R. Levi,et al.  Angiotensin-converting enzyme-independent angiotensin formation in a human model of myocardial ischemia: modulation of norepinephrine release by angiotensin type 1 and angiotensin type 2 receptors. , 2000, The Journal of pharmacology and experimental therapeutics.

[190]  G. Maurer,et al.  Plasma levels of C-reactive protein after coronary stent implantation. , 2000, European heart journal.

[191]  G. Mancia,et al.  Modulation of sympathetic coronary vasoconstriction by cardiac renin-angiotensin system in human coronary heart disease. , 2000, Circulation.

[192]  G. Stone,et al.  Prognostic value of cardiac troponin-I levels following catheter-based coronary interventions. , 2000, The American journal of cardiology.

[193]  M. Prins,et al.  UvA-DARE ( Digital Academic Repository ) Triage of patients for short term observation after elective coronary angioplasty , 2000 .

[194]  G. Stone,et al.  Long-term clinical events following creatine kinase--myocardial band isoenzyme elevation after successful coronary stenting. , 2000, Journal of the American College of Cardiology.

[195]  J. Freyssinet,et al.  Elevated levels of shed membrane microparticles with procoagulant potential in the peripheral circulating blood of patients with acute coronary syndromes. , 2000, Circulation.

[196]  R. Califf,et al.  Timing of and risk factors for myocardial ischemic events after percutaneous coronary intervention (IMPACT-II). Integrilin to Minimize Platelet Aggregation and Coronary Thrombosis. , 2000, The American journal of cardiology.

[197]  G. Stone,et al.  Atherosclerotic plaque burden and CK-MB enzyme elevation after coronary interventions : intravascular ultrasound study of 2256 patients. , 2000, Circulation.

[198]  E. Topol,et al.  Recognition of the importance of embolization in atherosclerotic vascular disease. , 2000, Circulation.

[199]  A. L'Abbate,et al.  Coronary microcirculatory vasoconstriction during ischemia in patients with unstable angina. , 2000, Journal of the American College of Cardiology.

[200]  U. Ikeda,et al.  Assessment of coagulation and platelet activation in coronary sinus blood induced by transcatheter coronary intervention for narrowing of the left anterior descending coronary artery. , 2000, The American journal of cardiology.

[201]  Y. Murakami,et al.  Troponin T In The Coronary Sinus And Percutaneous Transluminal Coronary Angioplasty Related Myocardial Injury , 2000, Clinical and experimental pharmacology & physiology.

[202]  O. Bertel,et al.  A double-blind, randomized study of the effect of immediate intravenous nitroglycerin on the incidence of postprocedural chest pain and minor myocardial necrosis after elective coronary stenting. , 2000, American heart journal.

[203]  Marshall A. Lichtman,et al.  Commentary on and reprint of EPIC (Evaluation of 7E3 for the Prevention of Ischemic Complications) Investigators, The, Use of monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty, in New England Journal of Medicine (1994) 330:956–961 , 2000 .

[204]  G. Stone,et al.  Creatine kinase-MB enzyme elevation following successful saphenous vein graft intervention is associated with late mortality. , 1999, Circulation.

[205]  R. Califf,et al.  Outcomes at 1 year and economic implications of platelet glycoprotein IIb/IIIa blockade in patients undergoing coronary stenting: results from a multicentre randomised trial , 1999, The Lancet.

[206]  F. Rengo,et al.  Intracoronary serotonin release after high-pressure coronary stenting. , 1999, The American journal of cardiology.

[207]  A. Lincoff,et al.  Chest pain--a strong predictor of adverse cardiac events following precutaneous intervention (from the Evaluation of Platelet IIb/IIIa Inhibitor for Stenting Trial [EPISENT])]. , 1999, The American journal of cardiology.

[208]  R. Califf,et al.  Platelet glycoprotein IIb/IIIa receptor inhibition in non-ST-elevation acute coronary syndromes: early benefit during medical treatment only, with additional protection during percutaneous coronary intervention. , 1999, Circulation.

[209]  P. Pasqualetti,et al.  Preprocedural serum levels of C-reactive protein predict early complications and late restenosis after coronary angioplasty. , 1999, Journal of the American College of Cardiology.

[210]  R. de Caterina,et al.  Endothelin-1 release from atherosclerotic plaque after percutaneous transluminal coronary angioplasty in stable angina pectoris and single-vessel coronary artery disease. , 1999, The American journal of cardiology.

[211]  Samin K. Sharma,et al.  Incidence and mechanism of creatine kinase‐MB enzyme elevation after coronary intervention with different devices , 1999 .

[212]  A. M. Lefer,et al.  Cardioprotective effects of abciximab (ReoPro) in an isolated perfused rat heart model of ischemia and reperfusion. , 1999, Methods and findings in experimental and clinical pharmacology.

[213]  B. Iung,et al.  Frequency and prognostic value of cardiac troponin I elevation after coronary stenting. , 1999, The American journal of cardiology.

[214]  Samin K. Sharma,et al.  Creatine kinase-MB elevation after coronary intervention correlates with diffuse atherosclerosis, and low-to-medium level elevation has a benign clinical course: implications for early discharge after coronary intervention. , 1999, Journal of the American College of Cardiology.

[215]  P. Teirstein,et al.  Retrieval and analysis of particulate debris after saphenous vein graft intervention. , 1999, Journal of the American College of Cardiology.

[216]  R. Califf,et al.  Minimal myocardial damage during coronary intervention is associated with impaired outcome. , 1999, European heart journal.

[217]  P. Fabbro-Péray,et al.  Relation of minor cardiac troponin I elevation to late cardiac events after uncomplicated elective successful percutaneous transluminal coronary angioplasty for angina pectoris. , 1999, The American journal of cardiology.

[218]  C. Di Mario,et al.  Prevention of distal embolization during saphenous vein graft lesion angioplasty. Experience with a new temporary occlusion and aspiration system. , 1999, Circulation.

[219]  C. Heeschen,et al.  Benefit of abciximab in patients with refractory unstable angina in relation to serum troponin T levels. c7E3 Fab Antiplatelet Therapy in Unstable Refractory Angina (CAPTURE) Study Investigators. , 1999, The New England journal of medicine.

[220]  W. Laskey Beneficial impact of preconditioning during PTCA on creatine kinase release. , 1999, Circulation.

[221]  R. Califf,et al.  Sustained suppression of ischemic complications of coronary intervention by platelet GP IIb/IIIa blockade with abciximab: one-year outcome in the EPILOG trial. Evaluation in PTCA to Improve Long-term Outcome with abciximab GP IIb/IIIa blockade. , 1999, Circulation.

[222]  G. Schulz,et al.  Influence of a platelet GPIIb/IIIa receptor antagonist on myocardial hypoperfusion during rotational atherectomy as assessed by myocardial Tc-99m sestamibi scintigraphy. , 1999, Journal of the American College of Cardiology.

[223]  R. Califf,et al.  The relationship between periprocedural myocardial infarction and subsequent target vessel revascularization following percutaneous coronary revascularization: insights from the EPIC trial. Evaluation of IIb/IIIa platelet receptor antagonist 7E3 in Preventing Ischemic Complications. , 1999, Journal of the American College of Cardiology.

[224]  W. Chilian,et al.  Endothelin antagonists block α1-adrenergic constriction of coronary arterioles. , 1999, American journal of physiology. Heart and circulatory physiology.

[225]  J. Freyssinet,et al.  Shed membrane microparticles with procoagulant potential in human atherosclerotic plaques: a role for apoptosis in plaque thrombogenicity. , 1999, Circulation.

[226]  R. Califf,et al.  Clinical outcomes after detection of elevated cardiac enzymes in patients undergoing percutaneous intervention , 1999 .

[227]  R. Califf,et al.  Clinical outcomes after detection of elevated cardiac enzymes in patients undergoing percutaneous intervention. IMPACT-II Investigators. Integrilin (eptifibatide) to Minimize Platelet Aggregation and Coronary Thrombosis-II. , 1999, Journal of the American College of Cardiology.

[228]  L. La Vecchia Sensitivity and long-term prognostic value of cardiac troponin I increase shortly after percutaneous transluminal coronary angioplasty. , 1999, Clinical cardiology.

[229]  G. Dangas,et al.  Incidence and mechanism of creatine kinase-MB enzyme elevation after coronary intervention with different devices. , 1999, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.

[230]  W. Chilian,et al.  Endothelin antagonists block alpha1-adrenergic constriction of coronary arterioles. , 1999, The American journal of physiology.

[231]  A. Jeremias,et al.  Nonischemic chest pain induced by coronary interventions: a prospective study comparing coronary angioplasty and stent implantation. , 1998, Circulation.

[232]  S. Steinhubl,et al.  The duration of pretreatment with ticlopidine prior to stenting is associated with the risk of procedure-related non-Q-wave myocardial infarctions. , 1998, Journal of the American College of Cardiology.

[233]  F. Crea,et al.  Predictive value of C-reactive protein after successful coronary-artery stenting in patients with stable angina. , 1998, The American journal of cardiology.

[234]  T. Investigators Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade. , 1998, Lancet.

[235]  E. Topol Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade , 1998, The Lancet.

[236]  D. Waters,et al.  Comparison of cardiac troponin I, creatine kinase-MB, and myoglobin for detection of acute ischemic myocardial injury in a swine model. , 1998, American journal of clinical pathology.

[237]  Remme Wj The sympathetic nervous system and ischaemic heart disease. , 1998 .

[238]  L. Vecchia Sensitivity and long‐term prognostic value of cardiac troponin i increase shortly after percutaneous transluminal coronary angioplasty , 1998 .

[239]  K. Shyu,et al.  Cardiac troponin T, creatine kinase, and its isoform release after successful percutaneous transluminal coronary angioplasty with or without stenting. , 1998, American heart journal.

[240]  A. Zanchetti,et al.  Postischemic left ventricular dysfunction is abolished by alpha-adrenergic blocking agents. , 1998, Journal of the American College of Cardiology.

[241]  W. Schaper,et al.  Tumor necrosis factor-alpha is expressed by monocytes/macrophages following cardiac microembolization and is antagonized by cyclosporine , 1998, Basic Research in Cardiology.

[242]  E J Topol,et al.  Aortocoronary saphenous vein graft disease: pathogenesis, predisposition, and prevention. , 1998, Circulation.

[243]  H. Ohnishi,et al.  Low incidence of minor myocardial damage associated with coronary stenting detected by serum troponin T comparable to that with balloon coronary angioplasty. , 1998, Japanese heart journal.

[244]  Samin K. Sharma,et al.  Final results of the Balloon vs Optimal Atherectomy Trial (BOAT) , 1998, Circulation.

[245]  R. Califf,et al.  Myonecrosis after revascularization procedures. , 1998, Journal of the American College of Cardiology.

[246]  V. Paul,et al.  Recruited collateral channels are not responsible for ischemic preconditioning during single vessel angioplasty , 1998 .

[247]  H. Arnesen,et al.  Myocardial damage during percutaneous transluminal coronary angioplasty as evidenced by troponin T measurements. , 1998, European heart journal.

[248]  H. Arnesen,et al.  Markers of myocardial injury in blood following PTCA: a comparison of CKMB, cardiospecific troponin T and troponin I. , 1998, Scandinavian journal of clinical and laboratory investigation.

[249]  Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction. , 1998, The New England journal of medicine.

[250]  W. Remme The sympathetic nervous system and ischaemic heart disease. , 1998, European heart journal.

[251]  Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes. , 1998, The New England journal of medicine.

[252]  D. Tate,et al.  Assessment of platelet activation by coronary sinus blood sampling during balloon angioplasty and directional coronary atherectomy. , 1997, The American journal of cardiology.

[253]  J. Mair,et al.  Cardiac troponin I to diagnose percutaneous transluminal coronary angioplasty-related myocardial injury. , 1997, Clinica chimica acta; international journal of clinical chemistry.

[254]  T. Investigators Effects of platelet glycoprotein IIb/IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty. The RESTORE Investigators. Randomized Efficacy Study of Tirofiban for Outcomes and REstenosis. , 1997, Circulation.

[255]  David P Miller,et al.  Long-term Protection From Myocardial Ischemic Events in a Randomized Trial of Brief Integrin β3 Blockade With Percutaneous Coronary Intervention , 1997 .

[256]  David P Miller,et al.  Long-term protection from myocardial ischemic events in a randomized trial of brief integrin beta3 blockade with percutaneous coronary intervention. EPIC Investigator Group. Evaluation of Platelet IIb/IIIa Inhibition for Prevention of Ischemic Complication. , 1997, JAMA.

[257]  R. Chioin,et al.  Troponin T, creatine kinase MB mass, and creatine kinase MB isoform ratio in the detection of myocardial damage during non-surgical coronary revascularization. , 1997, International journal of cardiology.

[258]  Epilog Investigators,et al.  Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. , 1997, The New England journal of medicine.

[259]  Integrilin to Minimise Platelet Aggregation and Coronary Thrombosis-II Randomised placebo-controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention: IMPACT-II , 1997, The Lancet.

[260]  Stgrp Capture,et al.  Randomised placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: the CAPTURE study , 1997, The Lancet.

[261]  W. Leowattana,et al.  Cardiac troponin T concentration after coronary balloon angioplasty. , 1997, The American journal of cardiology.

[262]  Z. Ongen,et al.  The importance of acute phase proteins in acute coronary syndromes. , 1997, The American journal of cardiology.

[263]  J. Zweier,et al.  Coronary angioplasty results in leukocyte and platelet activation with adhesion molecule expression. Evidence of inflammatory responses in coronary angioplasty. , 1997, Journal of the American College of Cardiology.

[264]  J. Marco,et al.  The alpha-1 adrenergic blocking agent urapidil counteracts postrotational atherectomy "elastic recoil" where nitrates have failed. , 1997, The American journal of cardiology.

[265]  R. Bonow,et al.  Prognostic implication of creatine kinase elevation following elective coronary artery interventions. , 1997, JAMA.

[266]  P. Serruys,et al.  Low molecular weight heparin (reviparin) in percutaneous transluminal coronary angioplasty results of a randomized, double-blind, unfractionated heparin and placebo-controlled, multicenter trial (REDUCE trial)☆ , 1996 .

[267]  E. Topol,et al.  Significance of mild transient release of creatine kinase-MB fraction after percutaneous coronary interventions. , 1996, Circulation.

[268]  D. Waters,et al.  Factors associated with the release of cardiac troponin T following percutaneous transluminal coronary angioplasty , 1996, Clinical cardiology.

[269]  M. Leon,et al.  Effect of rotational atherectomy in noncalcified atherosclerotic plaque: a volumetric intravascular ultrasound study. , 1996, Journal of the American College of Cardiology.

[270]  D. Baim,et al.  Myocardial infarction as a complication of new interventional devices. , 1996, The American journal of cardiology.

[271]  F. Bedogni,et al.  Troponin T, troponin I and creatine kinase‐MB mass after elective coronary stenting , 1996, Coronary artery disease.

[272]  E. Topol,et al.  Defining the appropriate threshold of creatine kinase elevation after percutaneous coronary interventions. , 1996, American heart journal.

[273]  M. Leon,et al.  Axial plaque redistribution as a mechanism of percutaneous transluminal coronary angioplasty. , 1996, The American journal of cardiology.

[274]  C. Meisner,et al.  Low molecular weight heparin (reviparin) in percutaneous transluminal coronary angioplasty. Results of a randomized, double-blind, unfractionated heparin and placebo-controlled, multicenter trial (REDUCE trial). Reduction of Restenosis After PTCA, Early Administration of Reviparin in a Double-Blind , 1996, Journal of the American College of Cardiology.

[275]  Mintz,et al.  Frequency and Prognostic Importance of Creatine Phosphokinase Myocardial Isoforms after Successful Balloon and New Device Coronary Angioplasty. , 1996, The Journal of invasive cardiology.

[276]  M. Condorelli,et al.  Limb vasoconstriction after successful angioplasty of the left anterior descending coronary artery. , 1995, Circulation.

[277]  B. Chaitman,et al.  Treatment with bivalirudin (Hirulog) as compared with heparin during coronary angioplasty for unstable or postinfarction angina. Hirulog Angioplasty Study Investigators. , 1995, The New England journal of medicine.

[278]  J. Windle,et al.  Significance of cardiac troponin T release after percutaneous transluminal coronary angioplasty. , 1995, The American journal of cardiology.

[279]  R. Califf,et al.  Characteristics and consequences of myocardial infarction after percutaneous coronary intervention: insights from the Coronary Angioplasty Versus Excisional Atherectomy Trial (CAVEAT). , 1995, Journal of the American College of Cardiology.

[280]  D. Baim,et al.  Elevation of the creatine kinase myocardial isoform following otherwise successful directional coronary atherectomy and stenting. , 1994, The American journal of cardiology.

[281]  J. Marco,et al.  Coronary Vasoconstriction After Percutaneous Transluminal Coronary Angioplast Is Attenuated by Antiadrenergic Agents , 1994, Circulation.

[282]  Epic Investigators,et al.  Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. , 1994, The New England journal of medicine.

[283]  J. Ravkilde,et al.  Cardiac troponin T and CK-MB mass release after visually successful percutaneous transluminal coronary angioplasty in stable angina pectoris. , 1994, American heart journal.

[284]  K. Bailey,et al.  Coronary embolization after balloon angioplasty or thrombolytic therapy: an autopsy study of 32 cases. , 1993, Journal of the American College of Cardiology.

[285]  J. Douglas,et al.  Angiographic predictors of a rise in serum creatine kinase (distal embolization) after balloon angioplasty of saphenous vein coronary artery bypass grafts. , 1993, The American journal of cardiology.

[286]  J. Mair,et al.  Side-branch occlusion during percutaneous transluminal coronary angioplasty , 1992, The Lancet.

[287]  D. Baim,et al.  Frequency and outcome of chest pain after two new coronary interventions (atherectomy and stenting). , 1992, The American journal of cardiology.

[288]  B. Cummins,et al.  Release of creatine kinase-MB and cardiac specific troponin-I following percutaneous transluminal coronary angioplasty. , 1991, European heart journal.

[289]  L. Klein,et al.  Incidence and clinical significance of transient creatine kinase elevations and the diagnosis of non-Q wave myocardial infarction associated with coronary angioplasty. , 1991, Journal of the American College of Cardiology.

[290]  M. Stadius,et al.  Coronary artery vasoconstriction routinely occurs after percutaneous transluminal coronary angioplasty. A quantitative arteriographic analysis. , 1988, Circulation.

[291]  T. Ryan Guidelines for percutaneous transluminal coronary angioplasty. A report of the American College of Cardiology/American Heart Association Task Force on Assessment of Diagnostic and Therapeutic Cardiovascular Procedures (Subcommittee on Percutaneous Transluminal Coronary Angioplasty). , 1988, Journal of the American College of Cardiology.

[292]  D. Faxon,et al.  Percutaneous transluminal coronary angioplasty in 1985-1986 and 1977-1981. The National Heart, Lung, and Blood Institute Registry. , 1988, The New England journal of medicine.

[293]  E. Casiglia,et al.  Changes in myoglobin, creatine kinase and creatine kinase-MB after percutaneous transluminal coronary angioplasty for stable angina pectoris. , 1987, The American journal of cardiology.

[294]  M. Hori,et al.  Role of adenosine in hyperemic response of coronary blood flow in microembolization. , 1986, The American journal of physiology.

[295]  A. Jaffe,et al.  Paucity of subtle myocardial injury after angioplasty delineated with MB CK. , 1986, Catheterization and Cardiovascular Diagnosis.

[296]  J. Fallon,et al.  Creatine kinase release not associated with myocardial necrosis after short periods of coronary artery occlusion in conscious baboons. , 1985, Journal of the American College of Cardiology.

[297]  J. Oh,et al.  Creatine kinase release after successful percutaneous transluminal coronary angioplasty. , 1985, American heart journal.

[298]  J. Downey,et al.  Inability of metoprolol to achieve a sustained limitation of infarct size 24 h after coronary artery embolization in the closed chest dog. , 1984, Journal of cardiovascular pharmacology.

[299]  L. Bentivoglio Percutaneous transluminal coronary angioplasty. , 1979, Annals of internal medicine.

[300]  A Gruntzig,et al.  Transluminal dilatation of coronary-artery stenosis. , 1978, Lancet.